A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of "Shinbaro Capsule" Compared With Historical Data of "Celebrex Capsule" in Patients With Osteoarthritis

Trial Profile

A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of "Shinbaro Capsule" Compared With Historical Data of "Celebrex Capsule" in Patients With Osteoarthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs GCSB 5 (Primary) ; Celecoxib
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors GC Pharma; Green Cross
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 29 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 29 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top